CHRS

CHRS R&D Expense Growth

12.46%Fiscal year

Period ending:

CHRS FY R&D Growth (YoY)%
CHRS FY R&D Growth (YoY)198.47%-71.20%
2012-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods. Dates are period ends; a fiscal year may differ from a calendar year. Growth compares with the corresponding period one year earlier.

CHRS r&d expense growth history

Year-over-year research & development expense growth. The available annual fiscal periods series contains 14 observations from Dec 31, 2012 to Dec 31, 2025.

Coherus Oncology Inc R&D Expense Growth — Annual fiscal periods
Period endingR&D Expense Growth
12.4582%
-14.7118%
-45.1058%
-45.0963%
154.3482%
51.5681%
-14.5602%
-32.1142%
-36.1779%
19.4206%
172.3742%
150.0847%
-10.3394%
0%

Compare r&d expense growth

All CHRS financial metrics · CHRS stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.